Kiniksa Pharmaceuticals International, plc (KNSA): R&D Expense
$96.85M
Year ended 2025-12-31
$105.00M
Trailing 12 months to 2026-03-31
+13.9%
3-year compound annual growth
-2.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $96.85M | -13.2% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $111.62M | +46.7% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $76.10M | +16.2% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $65.49M | -34.0% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $99.30M | -11.4% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $112.04M | -17.0% | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | $135.00M | +55.9% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $86.60M | +53.7% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $56.36M | n/a | 2019-03-12, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $96.85M | -13.2% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $750.00M | +7.4% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $106.23M | -2.4% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $183.28M | -2.0% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $85.84M | +16.1% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $117.31M | +43.8% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $53.20M | -24.8% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $160.22M | +69.9% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $124.03M | +17.9% |
Compare KNSA, RARE, SUPN, AXSM side by side · Screen every company in Pharmaceutical Preparations ↗